MG
RIGL icon

Michael Gelband’s Rigel Pharmaceuticals RIGL Stock Holding History

Michael Gelband’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,851
Closed -$293K – 1978
2026
Q1 		$293K Buy
10,851
+4,269
+65% +$143K ﹤0.01% 1315
2025
Q4 		$282K Sell
6,582
-9,785
-60% -$369K ﹤0.01% 1323
2025
Q3 		$464K Buy
+16,367
New +$490K ﹤0.01% 1201
2025
Q1 		– Sell
-15,483
Closed -$260K – 1920
2024
Q4 		$260K Buy
+15,483
New +$297K ﹤0.01% 1316
2023
Q1 		– Sell
-4,016
Closed -$60K – 2070
2022
Q4 		$60K Sell
4,016
-31,308
-89% -$287K ﹤0.01% 1540
2022
Q3 		$417K Buy
+35,324
New +$478K 0.01% 1430
2022
Q2 		– Sell
-41,877
Closed -$1.25M – 2365
2022
Q1 		$1.25M Buy
41,877
+5,650
+16% +$153K 0.02% 1021
2021
Q4 		$960K Buy
36,227
+33,717
+1,343% +$1.02M 0.01% 1093
2021
Q3 		$91K Buy
+2,510
New +$98.8K ﹤0.01% 1916
2021
Q2 		– Sell
-2,647
Closed -$91K – 2729
2021
Q1 		$91K Sell
2,647
-321
-11% -$12.7K ﹤0.01% 1990
2020
Q4 		$104K Sell
2,968
-1,023
-26% -$29.6K ﹤0.01% 1828
2020
Q3 		$96K Buy
3,991
+1,681
+73% +$41.3K ﹤0.01% 1595
2020
Q2 		$42K Buy
+2,310
New +$41.6K ﹤0.01% 1690
2020
Q1 		– Sell
-1,112
Closed -$24K – 1555
2019
Q4 		$24K Buy
+1,112
New +$22.9K ﹤0.01% 1466
2019
Q3 		– Sell
-1,898
Closed -$50K – 1591
2019
Q2 		$50K Buy
+1,898
New +$42.8K ﹤0.01% 1052

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's RIGL Position: Q2 2026 in Review

Michael Gelband sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 10,851 shares — an estimated $293K sold.

Michael Gelband first reported a position in RIGL in Q2 2019 and held it in 15 quarters. The position peaked at $1.25M in Q1 2022. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Michael Gelband reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 10,851 Rigel Pharmaceuticals shares in Q2 2026, an estimated $293K.
  • Michael Gelband first reported a position in Rigel Pharmaceuticals in Q2 2019 and held it in 15 quarters.
  • Michael Gelband's Rigel Pharmaceuticals position peaked at $1.25M in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.